Eve Gillespie, MD
Cardiovascular Disease · Kalispell, MTNPI 1922038520
Payments from drug & device makers
Across 531 payments — averaging $2645.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$296K
- Merck$271K
- Novartis$261K
- Amgen$217K
- Bayer$135K
- Esperion Therapeutics, Inc.$124K
- plus $102K from 17 others
What the payments were for
- Food & beverage$1,17397%
- Education$323%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 96 | $295,641 |
| Merck | 29 | $270,558 |
| Novartis | 9 | $260,552 |
| Amgen | 21 | $216,945 |
| Bayer | 74 | $135,037 |
| Esperion Therapeutics, Inc. | 192 | $123,948 |
| Medtronic(2 entities) | 22 | $53,449 |
| Alnylam Pharmaceuticals Inc. | 11 | $25,470 |
| Impulse Dynamics (USA) Inc. | 8 | $22,209 |
| Biotronik Inc. | 14 | $207 |
| Boehringer Ingelheim | 15 | $165 |
| AstraZeneca | 7 | $147 |
| Johnson & Johnson | 10 | $140 |
| E.r. Squibb & Sons, L.L.C. | 5 | $85 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $84 |
| Actelion Pharmaceuticals US, Inc. | 3 | $52 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Amarin Pharma, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $17 |
| La Jolla Pharmaceutical Company | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| United Therapeutics Corporation | 1 | $14 |
How this compares
$1,404,820 in reported general payments places this provider in the 95th percentile of 49 cardiovascular disease providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 321 | $301,579 |
| VyndaqelTafamidis Meglumine | 11 | $245,655 |
| EntrestoSacubitril/Valsartan | 253 | $235,140 |
| XareltoRivaroxaban | 101 | $116,012 |
| Repatha SureclickEvolocumab | 82 | $56,848 |
| JardianceEmpagliflozin | 31 | $31,511 |
| Praluent PenAlirocumab | 47 | $23,229 |
| VerquvoVericiguat | 16 | $18,726 |
| CorlanorIvabradine Hcl | 16 | $8,306 |
| Metoprolol Succinate | 575 | $7,916 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 41 | $6,612 |
| Ezetimibe | 216 | $5,041 |
| PradaxaDabigatran Etexilate Mesylate | 20 | $5,012 |
| Potassium Chloride | 246 | $4,708 |
| Atorvastatin Calcium | 370 | $3,834 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $260,552 | $235,140253 claims |
| Johnson & JohnsonXarelto | $140 | $116,012101 claims |
| Boehringer IngelheimJardiance, Pradaxa | $165 | $36,52351 claims |
| MerckVerquvo | $270,558 | $18,72616 claims |
| AmgenCorlanor | $216,945 | $8,30616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 cardiovascular disease providers in Montana.
Other cardiovascular disease in Kalispell
- Robert MitchellKalispell$23K
- Rawa SarjiKalispell$2K
- Alexis HarrisonKalispell$1K
- Joseph KrezowskiKalispell$1K
- Sharon HeckerKalispell$290
- David RothKalispell$18
- Michael ReedMissoula$637K
- Benjamin PlankBillings$191K
- Jorge CastrizGreat Falls$73K
- Gregory WoodMissoula$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.